$CTIX Recent Headlines
Post# of 72747
Posted On: 09/24/2014 11:22:54 AM
$CTIX Recent Headlines
Update: Cellceutix Calls Out To President Obama About Brilacidin
3:38 p.m. Sept. 21, 2014
- Seeking Alpha
10-K: CELLCEUTIX CORP
1:53 p.m. Sept. 15, 2014
- Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
3:06 a.m. Sept. 14, 2014
- Seeking Alpha
The Antibiotic Resistance Triple Threat
2:05 p.m. Sept. 4, 2014
- Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial
9:45 a.m. Aug. 19, 2014
- Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?
11:38 a.m. Aug. 14, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
10:15 a.m. May 12, 2014
- Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix
10:34 a.m. April 25, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
5:09 p.m. Feb. 10, 2014
- Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin
10:31 a.m. Jan. 28, 2014
- Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward
4:17 p.m. Jan. 2, 2014
- Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014
10:06 a.m. Dec. 16, 2013
- Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference
6:38 a.m. Nov. 19, 2013
- Seeking Alpha
10-Q: CELLCEUTIX CORP
6:06 p.m. Nov. 8, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP
4:01 p.m. Sept. 30, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP
2:18 p.m. May 20, 2013
- Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich
9:57 a.m. Nov. 15, 2011
- GuruFocus.com
Cellceutix to President Obama: We Have the Tools and Will Rise Up to
the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a
Serious Threat to Public Health
7:15 a.m. Sept. 19, 2014
- Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b
Trial; Company Submits Investigational New Drug Application to FDA
for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
3:01 p.m. Sept. 9, 2014
- Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global
Investment Conference
11:17 a.m. Sept. 5, 2014
- Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as
Company Focuses on Meeting Requirements for Stock Exchange Uplisting
7:01 a.m. Sept. 2, 2014
- Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of
Brilacidin for Acute Bacterial Skin and Skin Structure Infections
(ABSSSI)
8:31 a.m. Aug. 19, 2014
- Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for
Oral Mucositis
7:01 a.m. Aug. 11, 2014
- Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of
Clinical Trial
6:04 a.m. Aug. 8, 2014
- Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling
Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial
for Acute Bacterial Skin and Skin Structure Infections Expected This
Month
7:01 a.m. Aug. 4, 2014
- Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel
Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot
Ulcers
7:01 a.m. July 14, 2014
- Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data
Safety Monitoring Board; Best Possible Outcome, No Treatment-Related
Serious Adverse Events (SAEs)
7:00 a.m. July 7, 2014
- Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
7:01 a.m. June 23, 2014
- Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering
Eighth Cohort
7:01 a.m. June 16, 2014
- Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
7:02 a.m. June 2, 2014
- Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic
Compounds With Leading Universities
7:02 a.m. May 27, 2014
- Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
7:01 a.m. May 19, 2014
- Marketwire
Cellceutix Confident in Its Formidable Antibiotic Arsenal
7:01 a.m. May 12, 2014
- Marketwire
Cohort Completed in Cellceutix Clinical Trial of Prurisol for
Psoriasis
5:56 a.m. May 7, 2014
- Marketwire
Top Five Daily Small Cap Trading List: InVivo Therapeutics Holding Corp, Vapor Group, Inc., Cellceutix Corp, Agenus, Magellan Petroleum Corp
10:02 a.m. April 29, 2014
- PR Newswire - PRF
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
9:08 a.m. April 28, 2014
- ACCESSWIRE
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant
Superbug Klebsiella Pneumoniae
6:31 a.m. April 14, 2014
- Marketwire
Update: Cellceutix Calls Out To President Obama About Brilacidin
3:38 p.m. Sept. 21, 2014
- Seeking Alpha
10-K: CELLCEUTIX CORP
1:53 p.m. Sept. 15, 2014
- Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
3:06 a.m. Sept. 14, 2014
- Seeking Alpha
The Antibiotic Resistance Triple Threat
2:05 p.m. Sept. 4, 2014
- Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial
9:45 a.m. Aug. 19, 2014
- Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?
11:38 a.m. Aug. 14, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
10:15 a.m. May 12, 2014
- Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix
10:34 a.m. April 25, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
5:09 p.m. Feb. 10, 2014
- Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin
10:31 a.m. Jan. 28, 2014
- Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward
4:17 p.m. Jan. 2, 2014
- Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014
10:06 a.m. Dec. 16, 2013
- Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference
6:38 a.m. Nov. 19, 2013
- Seeking Alpha
10-Q: CELLCEUTIX CORP
6:06 p.m. Nov. 8, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP
4:01 p.m. Sept. 30, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP
2:18 p.m. May 20, 2013
- Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich
9:57 a.m. Nov. 15, 2011
- GuruFocus.com
Cellceutix to President Obama: We Have the Tools and Will Rise Up to
the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a
Serious Threat to Public Health
7:15 a.m. Sept. 19, 2014
- Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b
Trial; Company Submits Investigational New Drug Application to FDA
for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
3:01 p.m. Sept. 9, 2014
- Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global
Investment Conference
11:17 a.m. Sept. 5, 2014
- Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as
Company Focuses on Meeting Requirements for Stock Exchange Uplisting
7:01 a.m. Sept. 2, 2014
- Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of
Brilacidin for Acute Bacterial Skin and Skin Structure Infections
(ABSSSI)
8:31 a.m. Aug. 19, 2014
- Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for
Oral Mucositis
7:01 a.m. Aug. 11, 2014
- Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of
Clinical Trial
6:04 a.m. Aug. 8, 2014
- Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling
Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial
for Acute Bacterial Skin and Skin Structure Infections Expected This
Month
7:01 a.m. Aug. 4, 2014
- Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel
Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot
Ulcers
7:01 a.m. July 14, 2014
- Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data
Safety Monitoring Board; Best Possible Outcome, No Treatment-Related
Serious Adverse Events (SAEs)
7:00 a.m. July 7, 2014
- Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
7:01 a.m. June 23, 2014
- Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering
Eighth Cohort
7:01 a.m. June 16, 2014
- Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
7:02 a.m. June 2, 2014
- Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic
Compounds With Leading Universities
7:02 a.m. May 27, 2014
- Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
7:01 a.m. May 19, 2014
- Marketwire
Cellceutix Confident in Its Formidable Antibiotic Arsenal
7:01 a.m. May 12, 2014
- Marketwire
Cohort Completed in Cellceutix Clinical Trial of Prurisol for
Psoriasis
5:56 a.m. May 7, 2014
- Marketwire
Top Five Daily Small Cap Trading List: InVivo Therapeutics Holding Corp, Vapor Group, Inc., Cellceutix Corp, Agenus, Magellan Petroleum Corp
10:02 a.m. April 29, 2014
- PR Newswire - PRF
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
9:08 a.m. April 28, 2014
- ACCESSWIRE
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant
Superbug Klebsiella Pneumoniae
6:31 a.m. April 14, 2014
- Marketwire
(0)
(0)